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Inflammation is an important contributor to lung tumor development
and progression. In addition, inflammatory signaling may promote
epithelial to mesenchymal transition, development of aggressive
metastatic tumor phenotypes, and play a role in resistance to targeted
therapies. New insights in inflammatory signaling have led to the
evaluation of combination therapies that target these specific path-
ways. In addition to developing the optimal combination of targeted
agents, biomarker-based selection of patients who will likely benefit
will be critical to the success of this strategy. Here we focus on the
potential contribution of inflammatory mediator-induced resistance
to epidermal growth factor receptor tyrosine kinase inhibitors.
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Targeted therapies for non–small-cell lung cancer (NSCLC),such as epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKI), have become important therapeutic
options; however, the overall initial response rate is low and
development of resistance is common.1,2 It has recently been
suggested that resistance to targeted therapies may be overcome
by identifying optimal combinations of drugs that target specific
molecules.3–5
Although underlying molecular mechanisms are not
fully understood, substantial experimental data suggest a
contributing role for inflammation in lung carcinogenesis.6
Certain inflammatory mediators also pave the way for epi-
thelial to mesenchymal transition (EMT), the developmental
shift from a polarized epithelial phenotype to a highly motile
mesenchymal phenotype essential in embryogenesis, organ
development, and cancer progression.7 Recent work indicates
that the progression of EMT, including loss of E-cadherin,
may also promote resistance to EGFR TKI in NSCLC. In
contrast, restoration of gene expression associated with the
epithelial phenotype can sensitize NSCLC cells to targeted
therapies.8–10 Thus, identifying the specific inflammatory
signals governing EMT and EGFR TKI resistance maybe an
important step toward expanding response to these agents.
The inflammatory enzyme cyclooxygenase-2 (COX-2)
is frequently over-expressed in a variety of malignancies11
and plays a multifaceted role in conferring malignant and
metastatic phenotypes.12 For example, COX-2 expression in
NSCLC is associated with apoptosis resistance,13 angiogen-
esis,14,15 and metastasis.16,17 These tumorigenic effects are, in
part, mediated by the COX-2 metabolite, prostaglandin E2
(PGE2), which is abundant in the lung tumor microenviron-
ment. Inflammatory and tumorigenic signaling often con-
verges on the mitogen-activated protein kinase/extracellular
signal-regulated kinase (MAPK/Erk) cascade.18 EGFR trans-
mits mitogenic signals from the cell surface to the nucleus by
activating MAPK/Erk (Figure 1), and PGE2 induces rapid
Erk phosphorylation in lung cancer cells.19 Recent studies
have shown that PGE2 and other inflammatory mediators de-
rived from neoplastic as well as stromal and immune cells
reduce tumor E-cadherin levels via MAPK/Erk-dependent up-
regulation of the transcriptional repressors zinc-finger E-box
binding homeobox 1 (ZEB-1) and zinc-finger factor Snail ho-
mologue 1 (Snail) in NSCLC, whereas COX-2 inhibitors reverse
this effect.20,21 Loss of E-cadherin is a hallmark of EMT and is
also associated with tumor progression and metastasis.7,22 High
E-cadherin expression or a gene signature associated with a
mesenchymal rather than epithelial phenotype is associated with
sensitivity to EGFR TKI in NSCLC.8–10 Therefore, PGE2 or
other inflammatory cytokines in the tumor microenvironment
may contribute to EGFR TKI resistance in NSCLC by suppress-
ing E-cadherin expression.
PGE2 exerts its effects through four G-protein coupled
receptors (GPCRs) designated E-prostanoid receptors (EP) 1
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FIGURE 1. Mechanisms of EGFR-dependent and independent MAPK/Erk pathway activation by PGE2. Epidermal growth fac-
tor receptor (EGFR) belongs to the tyrosine kinase receptors family and is a major regulator of epithelial cell growth and prolif-
eration. It also plays an important role in tumorigenesis by promoting cancer cell proliferation, invasion, and metastasis. The
MAPK/Erk signaling module is located downstream of EGFR and is a critical effector of mitogenic signaling. PGE2 is a major
COX-2 metabolite abundantly present in the cancer microenvironment that exerts its effects through four G-protein coupled
receptors designated as EP1, EP2, EP3, and EP4 (area 1). PGE2 signaling can promote cell proliferation, migration, and EMT
by directly activating intracellular mitogenic pathways or by stimulating proteolytic release of extracellular growth factor re-
ceptor ligands that activate the mitogenic cell-surface receptors. In NSCLC, PGE2-induced MAPK/Erk activation occurs by the
intracellular pathway and is therefore EGFR-independent, encouraging resistance to EGFR TKI (area 2). In contrast, in colon
cancer, PGE2 can induce EGFR ligand release, activating the receptor to increase MAPK/Erk signaling through a mechanism
that is sensitive to EGFR inhibition (area 3). Here the scissors indicate MMP-induced release of cell membrane-bound EGFR
ligands that can occur in colon cancer. Inhibition of COX-2 abrogates both EGFR-dependent and independent PGE2-induced
MAPK/Erk activation in NSCLC (area 1). COX-2: cyclooxygenase-2 (selectively inhibited by COX-2 inhibitors such as cele-
coxib); PGE2: prostaglandin E2; EP: E-prostanoid receptors; , , and , G-proteins: components of the G-protein coupled re-
ceptors; EGFR, epidermal growth factor receptor (P indicates tyrosines phosphorylated upon receptor activation; this process is
blocked by tyrosine kinase inhibitors such as erlotinib); Ras: Ras small guanosine triphosphatase; Raf: Raf serine/threonine ki-
nase; MEK: MAPK/Erk kinase; Erk: extracellular signal-regulated kinase; PKC: protein kinase C; MMP: matrix metalloproteinase;
EMT: epithelial to mesenchymal transition.
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to 4 (Figure 1, area 1).23 Recent studies indicate that GPCRs
can activate the MAPK/Erk cascade in either a receptor
tyrosine kinase (RTK)-dependent or independent manner
(summarized in Refs. 24–26). Activation of EGFR signaling
by PGE2 in lung cancer appears to occur via intracellular
cross-talk between EP receptors and signaling modules down-
stream of EGFR such as MAPK/Erk (Figure 1, area 2).19 This is
in contrast to the pathways defined in colon cancer in which
PGE2 stimulates proteolytic release of EGFR ligands27,28 or
intracellular src-dependent signaling29 (Figure 1, area 3). Thus,
in NSCLC, intracellular cross-talk between PGE2 and MAPK/
Erk may directly contribute to EGFR TKI resistance. Indeed,
PGE2 encourages resistance to the antiproliferative effects of the
EGFR TKI erlotinib, and this can be overcome by concurrent
targeting of the COX-2 pathway in NSCLC cell lines.19 These
data provide a strong rationale for simultaneously targeting
EGFR and COX-2 for lung cancer treatment.30
Clinical trials targeting EGFR and COX-2 have re-
cently been reported. Gadgeel et al. conducted a Phase II trial
evaluating combined therapy with the EGFR TKI, gefitinib,
and celecoxib in platinum-refractory NSCLC patients, and
found that response rates and survival with the combination
therapy were similar to those observed with gefitinib alone.
Patients receiving combination therapies were treated with
gefitinib 250 mg daily and celecoxib 400 mg twice daily.31
O’Byrne et al. reported a disease control rate of 35% in
relapsed, metastatic NSCLC patients treated with escalating
doses of rofecoxib (12.5, 25, or 50 mg/d) combined with
gefitinib (250 mg/d). The combination therapy provided dis-
ease control rates equivalent to that expected for EGFR TKI
single agent therapy.32 These two studies may not have
employed the optimal biologic dose to inhibit COX-2. Reckamp
et al reported a phase I trial evaluating escalating doses of
celecoxib (200–800 mg twice daily) in combination with the
fixed dose of erlotinib (150 mg/d) in late stage NSCLC patients
and established the optimal biologic dose of celecoxib to be 600
mg twice daily, defined as the maximal decrease in urinary
prostaglandin E metabolite.33 This study revealed an acceptable
toxicity profile with the combination therapy and demonstrated
a disease control rate above that expected for erlotinib alone.
Based on these results, a phase II trial has been recently opened
assessing combination therapy with celecoxib at 600 mg twice
daily and erlotinib versus single agent erlotinib.
Signaling via other RTKs such as hepatocyte growth
factor receptor (MET) and vascular endothelial growth factor
receptor may increase tumor COX-2 expression.34–37 MET
amplification has recently been implicated in acquired EGFR
TKI resistance in NSCLC.2 Up-regulation of COX-2 expres-
sion by RTK may provide additional mitogenic stimuli via
the inflammation-dependent mechanisms described above. In
addition, MET,38 VEGF,39 and other RTK40,41 pathways may
be activated by cross-talk with GPCRs. Detailed molecular
mechanisms underlying these effects are currently under
investigation.
Inflammatory and RTK signaling pathways form com-
plex networks with multiple overlapping modules. PGE2/
EGFR cross-signaling has been one of the most extensively
studied relationships between these pathways. The results of
preclinical studies support the hypothesis that simultaneous
targeting of COX-2 and EGFR pathways may improve re-
sponse in certain NSCLC patients. Thus far, this concept has
been difficult to translate into clinical benefit. However, discov-
ery of biomarkers that predict response to this approach may
improve outcomes by allowing selection of patients who are
most likely to benefit.42–44
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